New Technologies and Approaches in Obesity Management

The high and growing rate of obesity incidence worldwide and its commensurate costs are driving development and use of multiple treatment options spanning surgery, medical devices and drugs, according to a new MedMarket Diligence report.
 
 
Spread the Word
Listed Under

Tags:
Obesity
Bariatric
Lapband
Bmi
Gastric Bypass

Industrys:
Reports
Business
Medical

Location:
California - US

March 7, 2011 - PRLog -- With high visibility rejections of obesity drugs by the FDA and withdrawals from the market, one might conclude that the obesity treatment options are limited, but this is far from the truth.  A wide variety of surgical procedures, medical devices and, indeed, drugs (accounting for over $800 million in sales annually) are available and in widespread use to address obesity and encompass satiety drugs, malabsorption drugs (and soon combination drugs), restrictive devices, artificial fullness devices, malabsorption devices, gastric emptying devices and appetite suppression devices.

“In 2011, 2012 and beyond, we see very specific events taking place that will bring new technologies and approaches reaching the market for obesity treatment, effectively expand the opportunities to address this serious condition,” says Patrick Driscoll, President of MedMarket Diligence, publisher of the 2011 worldwide report, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”  According to Driscoll, this will result in sales of specific obesity product treatment types grow annually, in most cases, well above double-digit rates.

The Americas currently represent the lion’s share of the global obesity products market, but as economies rapidly grow outside of the Americas, particularly in China, the relative share of the Americas market will noticeably shift toward Asia/Pacific.

At least fifty companies are active in the field of obesity management, marketing current products and/or with products in active development.  Given the market’s expansion, driven by incidence/prevalence trends, growing evidence of the co-morbidities of obesity, the support under most reimbursement schemes globally, and other forces, it is expected that the number of competitors will steadily ramp up for several years before market consolidation becomes evident.

The MedMarket Diligence report, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019,” is described in detail at http://www.mediligence.com/rpt/rpt-s835.htm.  The report is a comprehensive market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. (The report addresses the challenges to obesity drug approval, such as the FDA's February 2011 rejection of Orexigen's Contrave, and considers the realistic prospects for obesity drugs and their changing opportunities to succeed in the U.S. and international markets.) The report profiles the 45 leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

The report may be ordered for immediate download from http://www.mediligence.com/store/page35.html or may be purchased via this order form: https://www.mediligence.com/order_forms/s835_order.pdf.

# # #

MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database.
End
Email:***@mediligence.com Email Verified
Phone:949-859-3401
Tags:Obesity, Bariatric, Lapband, Bmi, Gastric Bypass
Industry:Reports, Business, Medical
Location:California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
MedMarket Diligence, LLC PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share